Mitochondrial involvement in antiretroviral therapy-related lipodystrophy

AIDS

Volumn 15, Issue 13, 2001, Pages 1643-1651

  Zaera, Montserrat Gómez ^a   Miró, Òscar ^b   Pedrol, Enric ^c   Soler, Anna ^c   Picón, Marta ^b   Cardellach, Francesc ^b   Casademont, Jordi ^b   Nunes, Virginia ^a,d  

^a Institut de Recerca Oncologica   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c 'Hospital Asil de Granollers' Foundation   (Spain)

^d HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Antiretroviral therapy; HIV; Lipodystrophy; Mitochondrial DNA deletions; Mitochondrial respiratory chain; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; MITOCHONDRIAL DNA; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; MITOCHONDRION; PRIORITY JOURNAL; RESPIRATORY CHAIN;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, MITOCHONDRIAL; FEMALE; GENE DELETION; HIV INFECTIONS; HIV-1; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL;

EID: 0035822947     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109070-00006     Document Type: Article

References (31)

1. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
2. Indinavir-associated lipodystrophy
3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
4. "Buffalo neck": An unintended secondary effect of treatment with anti-HIV protease inhibitors
5. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
6. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease
7. HIV-associated lipodystrophy syndrome
8. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
9. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
10. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
11. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
12. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction
13. Clinical, histological and molecular reversibility of zidovudine myopathy
14. Lipids and retroviruses
15. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
16. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
17. Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy
18. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
19. Muscle involvement in rheumatoid arthritis: Clinicopathological study of 21 symptomatic cases
20. Effects of general anaesthetic procedures on mitochondrial function of human skeletal muscle
21. Biochemical and molecular investigations in respiratory chain deficiencies
22. Biochemical parameters for the diagnosis of mitochondrial respiratory chain deficiency in humans, and their lack of age-related changes
23. Assessment of the mitochondrial respiratory chain
24. Sequence and organization of the human mitochondrial genome
25. A novel mitochondrial DNA mutation in the tRNASer(AGY) in multiple symmetric lipomatosis
26. Human immunodeficiency virus type 1 infection and myopathy: Clinical relevance of zidovudine therapy
27. Skeletal muscle involvement in HIV-infected patients
28. Early features of zidovudine-associated myopathy: Histopathological findings and clinical correlations
29. Zidovudine myopathy: A distinctive disorder associated with mitochondrial dysfunction
30. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC) on cultured human muscle cells
31. Zidovudine-induced experimental myopathy: Dual mechanism of mitochondrial damage